Aurinia Pharmaceuticals (AUPH) Total Liabilities (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Total Liabilities data on file, last reported at $156.4 million in Q1 2026.

• Quarterly Total Liabilities rose 1.11% year-over-year to $156.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.4 million (up 1.11% YoY) and the FY2025 annual result came in at $170.3 million, down 1.68% from the prior year.
• Total Liabilities slipped to $156.4 million in Q1 2026, from $170.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $173.2 million in Q4 2024 to a low of $58.4 million in Q2 2022.
• A 5-year average of $132.9 million and a median of $157.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities soared 168.26% — and 2025, when it slipped 1.68%.
• Tracing AUPH's Total Liabilities over 5 years: stood at $65.4 million in 2022, then jumped by 160.0% to $170.1 million in 2023, then grew by 1.8% to $173.2 million in 2024, then dropped by 1.68% to $170.3 million in 2025, then fell by 8.16% to $156.4 million in 2026.
• The last three Total Liabilities figures came in at $156.4 million (Q1 2026), $170.3 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.